U.S. Markets close in 14 mins.

GlaxoSmithKline plc (GSK)


NYSE - Nasdaq Real Time Price. Currency in USD
Add to watchlist
42.650-0.120 (-0.281%)
As of 3:46PM EDT. Market open.
People also watch
AZNNVSSNYLLYBMY
Full screen
Previous Close42.770
Open42.790
Bid42.610 x 1300
Ask42.620 x 2100
Day's Range42.370 - 42.820
52 Week Range37.200 - 45.580
Volume2,054,621
Avg. Volume2,783,782
Market Cap101.04B
Beta1.07
PE Ratio (TTM)48.03
EPS (TTM)N/A
Earnings DateN/A
Dividend & Yield1.95 (4.60%)
Ex-Dividend Date2017-05-10
1y Target EstN/A
Trade prices are not sourced from all markets
  • Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab
    Zacks21 hours ago

    Emergent Inks Agreement to Acquire Anthrax Drug Raxibacumab

    Emergent's shares inched up post announcement of its deal inked with GlaxoSmithKline to acquire the latter's anthrax monoclonal antibody raxibacumab.

  • These Non-Tech Firms Are Making Big Bets On Artificial Intelligence
    Investor's Business Dailyyesterday

    These Non-Tech Firms Are Making Big Bets On Artificial Intelligence

    Loup Ventures has compiled a portfolio of 17 publicly traded non-tech companies that are making investments in artificial intelligence to improve their businesses.

  • American City Business Journalsyesterday

    Emergent BioSolutions acquires GlaxoSmithKline anthrax drug for $96 million

    Gaithersburg-based Emergent BioSolutions has been on a bit of a buying spree lately. On Wednesday, the company announced it would acquire a drug for treating inhaled anthrax from pharmaceutical giant GlaxoSmithKline in an all-cash deal worth up to $96 million. The deal came less than a week after Emergent (EBS) announced it would buy French pharmaceutical giant Sanofi's smallpox vaccine business in an all-cash deal worth up to $125 million.